ADMA Biologics Statistics
Total Valuation
ADMA Biologics has a market cap or net worth of $4.88 billion. The enterprise value is $4.89 billion.
Important Dates
The last earnings date was Wednesday, May 7, 2025, after market close.
| Earnings Date | May 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ADMA Biologics has 238.73 million shares outstanding. The number of shares has increased by 8.72% in one year.
| Current Share Class | 238.73M |
| Shares Outstanding | 238.73M |
| Shares Change (YoY) | +8.72% |
| Shares Change (QoQ) | -0.50% |
| Owned by Insiders (%) | 1.88% |
| Owned by Institutions (%) | 85.35% |
| Float | 234.14M |
Valuation Ratios
The trailing PE ratio is 24.46 and the forward PE ratio is 26.43.
| PE Ratio | 24.46 |
| Forward PE | 26.43 |
| PS Ratio | 10.47 |
| Forward PS | 12.74 |
| PB Ratio | 13.06 |
| P/TBV Ratio | 13.21 |
| P/FCF Ratio | 53.84 |
| P/OCF Ratio | 48.21 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 30.57, with an EV/FCF ratio of 53.95.
| EV / Earnings | 23.65 |
| EV / Sales | 10.65 |
| EV / EBITDA | 30.57 |
| EV / EBIT | 32.16 |
| EV / FCF | 53.95 |
Financial Position
The company has a current ratio of 6.58, with a Debt / Equity ratio of 0.22.
| Current Ratio | 6.58 |
| Quick Ratio | 3.20 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | 0.51 |
| Debt / FCF | 0.90 |
| Interest Coverage | 12.53 |
Financial Efficiency
Return on equity (ROE) is 78.45% and return on invested capital (ROIC) is 25.32%.
| Return on Equity (ROE) | 78.45% |
| Return on Assets (ROA) | 22.06% |
| Return on Invested Capital (ROIC) | 25.32% |
| Return on Capital Employed (ROCE) | 33.26% |
| Revenue Per Employee | $670,629 |
| Profits Per Employee | $301,855 |
| Employee Count | 685 |
| Asset Turnover | 1.07 |
| Inventory Turnover | 1.25 |
Taxes
| Income Tax | -66.01M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +121.93% in the last 52 weeks. The beta is 0.57, so ADMA Biologics's price volatility has been lower than the market average.
| Beta (5Y) | 0.57 |
| 52-Week Price Change | +121.93% |
| 50-Day Moving Average | 20.48 |
| 200-Day Moving Average | 18.41 |
| Relative Strength Index (RSI) | 47.56 |
| Average Volume (20 Days) | 4,088,464 |
Short Selling Information
The latest short interest is 12.35 million, so 5.17% of the outstanding shares have been sold short.
| Short Interest | 12.35M |
| Short Previous Month | 13.26M |
| Short % of Shares Out | 5.17% |
| Short % of Float | 5.27% |
| Short Ratio (days to cover) | 3.09 |
Income Statement
In the last 12 months, ADMA Biologics had revenue of $459.38 million and earned $206.77 million in profits. Earnings per share was $0.84.
| Revenue | 459.38M |
| Gross Profit | 241.54M |
| Operating Income | 152.04M |
| Pretax Income | n/a |
| Net Income | 206.77M |
| EBITDA | 159.94M |
| EBIT | 152.04M |
| Earnings Per Share (EPS) | $0.84 |
Full Income StatementBalance Sheet
The company has $71.63 million in cash and $82.01 million in debt, giving a net cash position of -$10.39 million or -$0.04 per share.
| Cash & Cash Equivalents | 71.63M |
| Total Debt | 82.01M |
| Net Cash | -10.39M |
| Net Cash Per Share | -$0.04 |
| Equity (Book Value) | 373.42M |
| Book Value Per Share | 1.57 |
| Working Capital | 298.32M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $101.22 million and capital expenditures -$10.58 million, giving a free cash flow of $90.64 million.
| Operating Cash Flow | 101.22M |
| Capital Expenditures | -10.58M |
| Free Cash Flow | 90.64M |
| FCF Per Share | $0.38 |
Full Cash Flow StatementMargins
Gross margin is 52.58%, with operating and profit margins of 33.10% and 45.01%.
| Gross Margin | 52.58% |
| Operating Margin | 33.10% |
| Pretax Margin | 30.64% |
| Profit Margin | 45.01% |
| EBITDA Margin | 34.82% |
| EBIT Margin | 33.10% |
| FCF Margin | 19.73% |
Dividends & Yields
ADMA Biologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.72% |
| Shareholder Yield | -8.72% |
| Earnings Yield | 4.24% |
| FCF Yield | 1.86% |
Analyst Forecast
The average price target for ADMA Biologics is $24.25, which is 18.64% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $24.25 |
| Price Target Difference | 18.64% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 19.77% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ADMA Biologics has an Altman Z-Score of 17.19 and a Piotroski F-Score of 7.
| Altman Z-Score | 17.19 |
| Piotroski F-Score | 7 |